SK Biopharmaceuticals Co Ltd
326030
Company Profile
Business description
SK Biopharmaceuticals Co Ltd is a pharmaceutical company engaged in the research and development of new drugs for the treatment of central nervous system (CNS) disorders. The company is also researching the development of drugs to treat brain tumors, including metastatic tumors. Its drug pipeline includes Cenobamate, Solriamfetol, Carisbamate, Relenopride, SKL13865, SKL20540, SKL-PSY, and more.
Contact
221, Pangyoyeok-ro
Bundang-gu
Gyeonggi-do
Seongnam13494
KORT: +82 3180930114
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
269
Stocks News & Analysis
stocks
The ASX player evolving into a defensive haven
A well-timed simplification journey as boring evolves back in vogue.
stocks
12 picks for an income portfolio - Q1 2026 update
Passive income growth continues to exceed my target.
stocks
Strong guidance from undervalued ASX share
Shares surged after the announcement of first half fiscal 2026 guidance.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,174.10 | 12.00 | 0.13% |
| CAC 40 | 8,334.58 | 90.55 | -1.07% |
| DAX 40 | 24,381.42 | 320.82 | -1.30% |
| Dow JONES (US) | 49,447.43 | 868.71 | 1.79% |
| FTSE 100 | 10,605.69 | 61.94 | -0.58% |
| HKSE | 26,361.07 | 200.74 | 0.77% |
| NASDAQ | 24,468.48 | 365.78 | 1.52% |
| Nikkei 225 | 58,824.89 | 348.99 | 0.60% |
| NZX 50 Index | 12,915.45 | 9.78 | 0.08% |
| S&P 500 | 7,126.06 | 84.78 | 1.20% |
| S&P/ASX 200 | 8,953.30 | 13.60 | 0.15% |
| SSE Composite Index | 4,082.13 | 30.70 | 0.76% |